ERBB2 and breast neoplasm: Biological or genetic differences resulting from mutations in the PI3K pathway could account for the activated Akt tumors, in addition to mutations or loss of PTEN (phosphatase and tensin homolog deleted on chromosome 10) in HER2/neu-overexpressing breast tumors.